|Bid||0.00 x 0|
|Ask||0.00 x 0|
|Day's Range||2.20 - 2.31|
|52 Week Range||1.13 - 4.44|
|PE Ratio (TTM)||N/A|
|Earnings Date||Mar 9, 2018 - Mar 12, 2018|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||11.50|
These two biotechs are big losers so far this year. But which has the better shot at being a winner over the long run?
What Happened The U.S. Food and Drug Administration announced March 15 an Advance Notice of Proposed Rulemaking (ANPRM) to procure information to help set the maximum nicotine level for cigarettes to non-addictive ...
22nd Century Group, Inc. , a plant biotechnology company focused on tobacco harm reduction and Very Low Nicotine tobacco, announced today that the U.S. Food and Drug Administration has published in the Federal Register the FDA’s Advance Notice of Proposed Rulemaking to lower nicotine in cigarettes to minimally or non-addictive levels.
Tobacco, not marijuana, is this company's main focus now. But the reason the stock isn't soaring is a little complicated.
22nd Century Group, Inc. , a plant biotechnology company that is focused on tobacco harm reduction and hemp research, announced today that the Company filed its 2017 Annual Report on Form 10-K with the U.S.
While small-cap stocks, such as 22nd Century Group Inc (AMEX:XXII) with its market cap of US$311.38M, are popular for their explosive growth, investors should also be aware of their balanceRead More...
For long-term investors, assessing earnings trend over time and against industry benchmarks is more beneficial than examining a single earnings announcement at a point in time. Investors may find myRead More...
22nd Century Group, Inc. , a plant biotechnology company focused on tobacco harm reduction and Very Low Nicotine tobacco, announces the nicotine reduction mandate planned by the U.S.
NEW YORK, March 05, 2018-- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of ...
22nd Century Group, Inc. , a plant biotechnology company focused on tobacco harm reduction, will present at the 2018 Society for Research on Nicotine and Tobacco Annual Meeting results from a survey conducted by Harris Poll on behalf of 22nd Century Group.
NEW YORK, NY / ACCESSWIRE / February 13, 2018 / U.S. markets rallied on Monday, after posting its worst weekly decline in two years, as President Trump unveiled details from his long awaited $200 billion ...
22nd Century Group, Inc. , a plant biotechnology company focused on tobacco harm reduction and hemp/cannabis research, announced today that the Company will present at the BIO CEO & Investor Conference at the New York Marriott Marquis on Monday, February 12, 2018 at 2:00 PM EST.
22nd Century Group, Inc. , a plant biotechnology company focused on tobacco harm reduction, reports recent activity relevant to the nicotine reduction mandate planned by the US Food and Drug Administration .
- Smoking and Nicotine Addiction Still a Huge Problem in the U.S. with 480K Preventable Deaths Each Year; Pfizer's Smoking Cessation Drug Chantix has become a Nearly $1 billion Product Annually - Newly ...
We see a notable shift away from traditional large-cap pharmaceutical stocks to more specialized niches.
NEW YORK, NY / ACCESSWIRE / January 16, 2018 / Traders News Source, a leading independent equity research and corporate access firm focused on small and mid-cap public companies, is issuing a comprehensive ...
NEW YORK, NY / ACCESSWIRE / December 11, 2017 / U.S. markets were lifted Friday by a stronger-than-expected November jobs report, sending the Dow and the S&P 500 to new record highs. The Dow Jones Industrial ...
Categories: ETFs Yahoo FinanceGet full CapitalCube analysis *Disclaimer : This is as of previous day’s closing price. Technical Indicators Below is a quick look at 5 technical indicators for 22nd Century Group, Inc.. More studies are available on the Technical Chart. Indicator Signal Closing Price above/below 50 Day Moving Average Bullish Closing Price above/below 200 Day Moving Average ... Read more (Read more...)
22nd Century Group, Inc. , a plant biotechnology company focused on tobacco harm reduction and hemp/cannabis research, announced today the hiring of Juan Sanchez Tamburrino, Ph.D., as the Company’s Vice President of Research and Development.
Yahoo Finance's Seana Smith, Andy Serwer, Ethan Wolff-Mann and Dion Rabouin discuss why now could be a good time to invest in marijuana stocks.